GlassScriptPhysician profile
James Thomas Link
NPI 1063775104
$4,621.56
in general payments reported to CMS, 2019-2025
41 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,462 · 2020: $1,602 · 2021: $1,428 · 2022: $89.13 · 2023: $25.00 · 2024: $15.48.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $25.00 · Food and Beverage: $15.48.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $25.00 |
| Food and Beverage | $15.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $426.34 | 2019-2021 | |
| Janssen Biotech, INC. | $401.44 | 2019-2022 | |
| Astellas Pharma US INC | $322.79 | 2020-2022 | |
| Seagen INC. | $269.99 | 2019-2021 | |
| Genzyme Corporation | $250.54 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $241.30 | 2019-2021 | |
| Genentech USA, INC. | $237.84 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $187.81 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $158.99 | 2019 | |
| Incyte Corporation | $155.39 | 2019-2021 | |
| Eisai INC. | $153.65 | 2020-2021 | |
| Pfizer INC. | $153.27 | 2019-2023 | |
| Glaxosmithkline, LLC. | $144.76 | 2020-2021 | |
| Exelixis INC. | $144.62 | 2019-2021 | |
| Puma Biotechnology, INC. | $139.29 | 2019-2021 |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Link listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.